Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Breast 1

Conditions

Tuberculosis, Pulmonary 1Non-Small Cell Lung Cancer NSCLC 1Lung Neoplasms 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × alfatide II × Thoracic × Clear all
NCT06416852 2024-05-16

Clinical Study of 18F-Alfatide Injection PET/CT

Yantai LNC Biotechnology Singapore PTE. LTD.

Phase 3 Not yet recruiting
428 enrolled
Thoracic

Non-Small Cell Lung Cancer NSCLC

NCT02481726 2015-06-25

68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT

Xijing Hospital

Phase 1/2 Completed
31 enrolled
Thoracic

Lung Neoplasms, Tuberculosis, Pulmonary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡